17.03.2020 19:20:00
|
Sartorius Stedim Biotech Postpones Annual Shareholders' Meeting
AUBAGNE, France, March 17, 2020 /PRNewswire/ -- Sartorius Stedim Biotech S.A. will postpone its Annual General Shareholders' Meeting formerly scheduled for March 24, 2020, to a later date due to the coronavirus pandemic and the associated restrictions imposed on travel and meetings. This was resolved today by the Board of Directors of the company.
As a result of the cancelation of the Annual General Shareholders' Meeting on March 24, 2020, the vote on the resolution on the assignment of the financial result for the year ended December 31, 2019, and the payment of dividends, among other things, will also be deferred.
The 2020 Annual General Shareholders' Meeting is to be scheduled for a new date within six months after the close of the fiscal year ending on December 31, 2019 as provided for under the French Commercial Law. Sartorius Stedim Biotech will inform its shareholders and the public in a timely manner about its further planning.
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of €1,440.6 million according to preliminary figures.
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.
Contact:
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
www.sartorius.com
View original content:http://www.prnewswire.com/news-releases/sartorius-stedim-biotech-postpones-annual-shareholders-meeting-301025703.html
SOURCE Sartorius Stedim Biotech S.A
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sartorius Stedim Biotechmehr Nachrichten
17.10.24 |
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2024 (EQS Group) | |
16.10.24 |
Ausblick: Sartorius Stedim Biotech zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
04.10.24 |
ANALYSE-FLASH: RBC lässt Sartorius Stedim Biotech auf 'Outperform' (dpa-AFX) | |
03.10.24 |
ANALYSE-FLASH: Goldman startet Sartorius Stedim Biotech mit 'Buy', Ziel 225 Euro (dpa-AFX) | |
02.10.24 |
Erste Schätzungen: Sartorius Stedim Biotech gewährt Anlegern Blick in die Bücher (finanzen.net) | |
18.07.24 |
Half-year results 2024 of SartoriusStedimBiotech (EQS Group) | |
18.07.24 |
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024 (EQS Group) | |
18.07.24 |
Ausblick: Sartorius Stedim Biotech vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Sartorius Stedim Biotechmehr Analysen
22.10.24 | Sartorius Stedim Biotech Neutral | UBS AG | |
17.10.24 | Sartorius Stedim Biotech Buy | Goldman Sachs Group Inc. | |
03.10.24 | Sartorius Stedim Biotech Buy | Goldman Sachs Group Inc. | |
03.10.24 | Sartorius Stedim Biotech Neutral | UBS AG | |
02.09.24 | Sartorius Stedim Biotech Outperform | RBC Capital Markets |